What is Circa Bioscience?
Circa Bioscience, LLC is a bioengineering firm specializing in the development of advanced diagnostic, screening, and monitoring technologies for neurodevelopmental and metabolic diseases. The company's core focus lies in the identification and validation of disease-specific biomarkers, with a particular emphasis on conditions such as autism spectrum disorder (ASD). Circa Bioscience's innovative solutions are engineered for versatile application across clinical settings, research laboratories, and home-based use, aiming to deepen the understanding and improve the management of these complex conditions through precise biomarker measurement.
How much funding has Circa Bioscience raised?
Circa Bioscience has raised a total of $18K across 1 funding round:
Debt
$18K
Debt (2021): $18K with participation from PPP
Key Investors in Circa Bioscience
PPP
Public-Private Partnership
What's next for Circa Bioscience?
With its recent debt financing, Circa Bioscience is positioned to accelerate its growth trajectory and further refine its diagnostic technologies. The company's focus on neurodevelopmental and metabolic diseases, including ASD, addresses a critical unmet need in healthcare. Future strategic initiatives will likely involve expanding the application of their biomarker measurement platforms, forging clinical partnerships, and potentially seeking further equity investment to scale commercialization efforts and broaden market reach. The company's commitment to innovation in this specialized bioengineering sector suggests a strong potential for future development and impact.
See full Circa Bioscience company page
